Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Molecular Pain
Published in: Molecular Pain 1/2009

Open Access 01-12-2009 | Review

Dynamic regulation of the endocannabinoid system: implications for analgesia

Authors: Devi Rani Sagar, A Gemma Gaw, Bright N Okine, Stephen G Woodhams, Amy Wong, David A Kendall, Victoria Chapman

Published in: Molecular Pain | Issue 1/2009

Login to get access

Abstract

The analgesic effects of cannabinoids are well documented, but these are often limited by psychoactive side-effects. Recent studies indicate that the endocannabinoid system is dynamic and altered under different pathological conditions, including pain states. Changes in this receptor system include altered expression of receptors, differential synthetic pathways for endocannabinoids are expressed by various cell types, multiple pathways of catabolism and the generation of biologically active metabolites, which may be engaged under different conditions. This review discusses the evidence that pain states alter the endocannabinoid receptor system at key sites involved in pain processing and how these changes may inform the development of cannabinoid-based analgesics.
Appendix
Available only for authorised users
Literature
1.
Mechoulam R, Gaoni Y: The absolute configuration of delta-1-tetrahydrocannabinol, the major active constituent of hashish. Tetrahedron Lett 1967, 12: 1109–1111. 10.1016/S0040-4039(00)90646-4PubMed
2.
Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI: Structure of a Cannabinoid Receptor and Functional Expression of the Cloned Cdna. Nature 1990, 346: 561–564. 10.1038/346561a0PubMed
3.
Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, et al.: International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors. Pharmacol Rev 2002, 54: 161–202. 10.1124/pr.54.2.161PubMed
4.
Egertova M, Elphick MR: Localisation of cannabinoid receptors in the rat brain using antibodies to the intracellular C-terminal tail of CB1. Journal of Comparative Neurology 2000, 422: 159–171. 10.1002/(SICI)1096-9861(20000626)422:2<159::AID-CNE1>3.0.CO;2-1PubMed
5.
6.
Johns DG, Behm DJ, Walker DJ, Ao Z, Shapland EM, Daniels DA, Riddick M, Dowell S, Staton PC, Green P, et al.: The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. Br J Pharmacol 2007, 152: 825–831. 10.1038/sj.bjp.0707419PubMedCentralPubMed
7.
Lauckner JE, Jensen JB, Chen HY, Lu HC, Hille B, Mackie K: GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci USA 2008, 105: 2699–2704. 10.1073/pnas.0711278105PubMedCentralPubMed
8.
Ryberg E, Larsson N, Sjogren S, Hjorth S, Hermansson NO, Leonova J, Elebring T, Nilsson K, Drmota T, Greasley PJ: The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 2007, 152: 1092–1101. 10.1038/sj.bjp.0707460PubMedCentralPubMed
9.
Ross RA: The enigmatic pharmacology of GPR55. Trends Pharmacol Sci 2009, 30: 156–163. 10.1016/j.tips.2008.12.004PubMed
10.
Caterina MJ, Julius D: The vanilloid receptor: a molecular gateway to the pain pathway. Annu Rev Neurosci 2001, 24: 487–517. 10.1146/annurev.neuro.24.1.487PubMed
11.
Potenzieri C, Brink TS, Simone DA: Excitation of cutaneous C nociceptors by intraplantar administration of anandamide. Brain Res 2009, 1268: 38–47. 10.1016/j.brainres.2009.02.061PubMedCentralPubMed
12.
Singh Tahim A, Santha P, Nagy I: Inflammatory mediators convert anandamide into a potent activator of the vanilloid type 1 transient receptor potential receptor in nociceptive primary sensory neurons. Neuroscience 2005, 136: 539–548. 10.1016/j.neuroscience.2005.08.005PubMed
13.
Alexander SP, Kendall DA: The complications of promiscuity: endocannabinoid action and metabolism. Br J Pharmacol 2007, 152: 602–623. 10.1038/sj.bjp.0707456PubMedCentralPubMed
14.
Lozovaya N, Min R, Tsintsadze V, Burnashev N: Dual modulation of CNS voltage-gated calcium channels by cannabinoids: Focus on CB1 receptor-independent effects. Cell Calcium 2009, 46: 154–162. 10.1016/j.ceca.2009.07.007PubMed
15.
Maingret F, Patel AJ, Lazdunski M, Honore E: The endocannabinoid anandamide is a direct and selective blocker of the background K(+) channel TASK-1. EMBO J 2001, 20: 47–54. 10.1093/emboj/20.1.47PubMedCentralPubMed
16.
Kim HI, Kim TH, Shin YK, Lee CS, Park M, Song JH: Anandamide suppression of Na+ currents in rat dorsal root ganglion neurons. Brain Res 2005, 1062: 39–47. 10.1016/j.brainres.2005.09.004PubMed
17.
Spivak CE, Lupica CR, Oz M: The endocannabinoid anandamide inhibits the function of alpha4beta2 nicotinic acetylcholine receptors. Mol Pharmacol 2007, 72: 1024–1032. 10.1124/mol.107.036939PubMed
18.
Racz I, Bilkei-Gorzo A, Markert A, Stamer F, Gothert M, Zimmer A: Anandamide effects on 5-HT(3) receptors in vivo. Eur J Pharmacol 2008, 596: 98–101. 10.1016/j.ejphar.2008.08.012PubMed
19.
Costa B, Comelli F, Bettoni I, Colleoni M, Giagnoni G: The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors. Pain 2008.
20.
Rockwell CE, Snider NT, Thompson JT, Heuvel JP, Kaminski NE: Interleukin-2 suppression by 2-arachidonyl glycerol is mediated through peroxisome proliferator-activated receptor gamma independently of cannabinoid receptors 1 and 2. Mol Pharmacol 2006, 70: 101–111.PubMed
21.
Russo R, LoVerme J, La Rana G, D'Agostino G, Sasso O, Calignano A, Piomelli D: Synergistic antinociception by the cannabinoid receptor agonist anandamide and the PPAR-alpha receptor agonist GW7647. Eur J Pharmacol 2007, 566: 117–119. 10.1016/j.ejphar.2007.03.007PubMedCentralPubMed
22.
Sun Y, Alexander SP, Garle MJ, Gibson CL, Hewitt K, Murphy SP, Kendall DA, Bennett AJ: Cannabinoid activation of PPAR alpha; a novel neuroprotective mechanism. Br J Pharmacol 2007, 152: 734–743. 10.1038/sj.bjp.0707478PubMedCentralPubMed
23.
O'Sullivan SE: Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. Br J Pharmacol 2007, 152: 576–582. 10.1038/sj.bjp.0707423PubMedCentralPubMed
24.
Cuzzocrea S, Mazzon E, Di Paola R, Peli A, Bonato A, Britti D, Genovese T, Muia C, Crisafulli C, Caputi AP: The role of the peroxisome proliferator-activated receptor-alpha (PPAR-alpha) in the regulation of acute inflammation. J Leukoc Biol 2006, 79: 999–1010. 10.1189/jlb.0605341PubMed
25.
Genovese T, Mazzon E, Di Paola R, Cannavo G, Muia C, Bramanti P, Cuzzocrea S: Role of endogenous ligands for the peroxisome proliferators activated receptors alpha in the secondary damage in experimental spinal cord trauma. Exp Neurol 2005, 194: 267–278. 10.1016/j.expneurol.2005.03.003PubMed
26.
Jhaveri MD, Richardson D, Robinson I, Garle MJ, Patel A, Sun Y, Sagar DR, Bennett AJ, Alexander SP, Kendall DA, et al.: Inhibition of fatty acid amide hydrolase and cyclooxygenase-2 increases levels of endocannabinoid related molecules and produces analgesia via peroxisome proliferator-activated receptor-alpha in a model of inflammatory pain. Neuropharmacology 2008, 55: 85–93. 10.1016/j.neuropharm.2008.04.018PubMed
27.
Sagar DR, Kendall DA, Chapman V: Inhibition of fatty acid amide hydrolase produces PPAR-alpha-mediated analgesia in a rat model of inflammatory pain. Br J Pharmacol 2008, 155: 1297–1306. 10.1038/bjp.2008.335PubMedCentralPubMed
28.
Staumont-Salle D, Abboud G, Brenuchon C, Kanda A, Roumier T, Lavogiez C, Fleury S, Remy P, Papin JP, Bertrand-Michel J, et al.: Peroxisome proliferator-activated receptor alpha regulates skin inflammation and humoral response in atopic dermatitis. J Allergy Clin Immunol 2008, 121: 962–968. 10.1016/j.jaci.2007.12.1165PubMed
29.
Galiegue S, Mary S, Marchand J, Dussossoy D, Carriere D, Carayon P, Bouaboula M, Shire D, Le Fur G, Casellas P: Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 1995, 232: 54–61. 10.1111/j.1432-1033.1995.tb20780.xPubMed
30.
Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, Decosta BR, Rice KC: Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 1990, 87: 1932–1936. 10.1073/pnas.87.5.1932PubMedCentralPubMed
31.
Herkenham M, Lynn AB, Johnson MR, Melvin LS, Decosta BR, Rice KC: Characterization and Localization of Cannabinoid Receptors in Rat-Brain - a Quantitative Invitro Autoradiographic Study. Journal of Neuroscience 1991, 11: 563–583.PubMed
32.
Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM: Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 1998, 83: 393–411. 10.1016/S0306-4522(97)00436-3PubMed
33.
Chin CL, Tovcimak AE, Hradil VP, Seifert TR, Hollingsworth PR, Chandran P, Zhu CZ, Gauvin D, Pai M, Wetter J, et al.: Differential effects of cannabinoid receptor agonists on regional brain activity using pharmacological MRI. Br J Pharmacol 2008, 153: 367–379. 10.1038/sj.bjp.0707506PubMedCentralPubMed
34.
Beltramo M, Bernardini N, Bertorelli R, Campanella M, Nicolussi E, Fredduzzi S, Reggiani A: CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms. Eur J Neurosci 2006, 23: 1530–1538. 10.1111/j.1460-9568.2006.04684.xPubMed
35.
Gong JP, Onaivi ES, Ishiguro H, Liu QR, Tagliaferro PA, Brusco A, Uhl GR: Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res 2006, 1071: 10–23. 10.1016/j.brainres.2005.11.035PubMed
36.
Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie K, Stella N, Makriyannis A, Piomelli D, Davison JS, et al.: Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 2005, 310: 329–332. 10.1126/science.1115740PubMed
37.
Pertwee RG: Cannabinoid receptors and pain. Prog Neurobiol 2001, 63: 569–611. 10.1016/S0301-0082(00)00031-9PubMed
38.
Iversen L, Chapman V: Cannabinoids: a real prospect for pain relief? Curr Opin Pharmacol 2002, 2: 50–55. 10.1016/S1471-4892(01)00120-5PubMed
39.
Walker JM, Huang SM: Cannabinoid analgesia. Pharmacol Ther 2002, 95: 127–135. 10.1016/S0163-7258(02)00252-8PubMed
40.
Hohmann AG, Tsou K, Walker JM: Cannabinoid modulation of wide dynamic range neurons in the lumbar dorsal horn of the rat by spinally administered WIN55,212–2. Neurosci Lett 1998, 257: 119–122. 10.1016/S0304-3940(98)00802-7PubMed
41.
Kelly S, Chapman V: Selective cannabinoid CB1 receptor activation inhibits spinal nociceptive transmission in vivo. J Neurophysiol 2001, 86: 3061–3064.PubMed
42.
Kelly S, Chapman V: Cannabinoid CB(1) receptor inhibition of mechanically evoked responses of spinal neurones in control rats, but not in rats with hindpaw inflammation. Eur J Pharmacol 2003, 474: 209–216. 10.1016/S0014-2999(03)02085-5PubMed
43.
Kelly S, Jhaveri MD, Sagar DR, Kendall DA, Chapman V: Activation of peripheral cannabinoid CB1 receptors inhibits mechanically evoked responses of spinal neurons in noninflamed rats and rats with hindpaw inflammation. Eur J Neurosci 2003, 18: 2239–2243. 10.1046/j.1460-9568.2003.02957.xPubMed
44.
Welch SP, Stevens DL: Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice. J Pharmacol Exp Ther 1992, 262: 10–18.PubMed
45.
Welch SP, Huffman JW, Lowe J: Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A. J Pharmacol Exp Ther 1998, 286: 1301–1308.PubMed
46.
Lichtman AH, Cook SA, Martin BR: Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaqueductal gray involvement. J Pharmacol Exp Ther 1996, 276: 585–593.PubMed
47.
Finn DP, Jhaveri MD, Beckett SR, Roe CH, Kendall DA, Marsden CA, Chapman V: Effects of direct periaqueductal grey administration of a cannabinoid receptor agonist on nociceptive and aversive responses in rats. Neuropharmacology 2003, 45: 594–604. 10.1016/S0028-3908(03)00235-1PubMed
48.
Martin WJ, Coffin PO, Attias E, Balinsky M, Tsou K, Walker JM: Anatomical basis for cannabinoid-induced antinociception as revealed by intracerebral microinjections. Brain Res 1999, 822: 237–242. 10.1016/S0006-8993(98)01368-7PubMed
49.
Meng ID, Manning BH, Martin WJ, Fields HL: An analgesia circuit activated by cannabinoids. Nature 1998, 395: 381–383. 10.1038/26481PubMed
50.
Agarwal N, Pacher P, Tegeder I, Amaya F, Constantin CE, Brenner GJ, Rubino T, Michalski CW, Marsicano G, Monory K, et al.: Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci 2007, 10: 870–879. 10.1038/nn1916PubMedCentralPubMed
51.
Kelly S, Chapman V: Spinal administration of capsazepine inhibits noxious evoked responses of dorsal horn neurons in non-inflamed and carrageenan inflamed rats. Brain Res 2002, 935: 103–108. 10.1016/S0006-8993(02)02552-0PubMed
52.
Scott DA, Wright CE, Angus JA: Evidence that CB-1 and CB-2 cannabinoid receptors mediate antinociception in neuropathic pain in the rat. Pain 2004, 109: 124–131. 10.1016/j.pain.2004.01.020PubMed
53.
Clayton N, Marshall FH, Bountra C, O'Shaughnessy CT: CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain. Pain 2002, 96: 253–260. 10.1016/S0304-3959(01)00454-7PubMed
54.
Elmes SJ, Winyard LA, Medhurst SJ, Clayton NM, Wilson AW, Kendall DA, Chapman V: Activation of CB1 and CB2 receptors attenuates the induction and maintenance of inflammatory pain in the rat. Pain 2005, 118: 327–335. 10.1016/j.pain.2005.09.005PubMed
55.
Richardson JD, Kilo S, Hargreaves KM: Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain 1998, 75: 111–119. 10.1016/S0304-3959(97)00213-3PubMed
56.
Akopian AN, Ruparel NB, Patwardhan A, Hargreaves KM: Cannabinoids desensitize capsaicin and mustard oil responses in sensory neurons via TRPA1 activation. J Neurosci 2008, 28: 1064–1075. 10.1523/JNEUROSCI.1565-06.2008PubMed
57.
Guindon J, Hohmann AG: Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br J Pharmacol 2008, 153: 319–334. 10.1038/sj.bjp.0707531PubMedCentralPubMed
58.
Jhaveri MD, Sagar DR, Elmes SJ, Kendall DA, Chapman V: Cannabinoid CB(2) Receptor-Mediated Anti-nociception in Models of Acute and Chronic Pain. Mol Neurobiol 2007, 36: 26–35. 10.1007/s12035-007-8007-7PubMed
59.
Ibrahim MM, Rude ML, Stagg NJ, Mata HP, Lai J, Vanderah TW, Porreca F, Buckley NE, Makriyannis A, Malan TP Jr: CB2 cannabinoid receptor mediation of antinociception. Pain 2006, 122: 36–42. 10.1016/j.pain.2005.12.018PubMed
60.
Malan TP Jr, Ibrahim MM, Deng H, Liu Q, Mata HP, Vanderah T, Porreca F, Makriyannis A: CB2 cannabinoid receptor-mediated peripheral antinociception. Pain 2001, 93: 239–245. 10.1016/S0304-3959(01)00321-9PubMed
61.
Valenzano KJ, Tafesse L, Lee G, Harrison JE, Boulet JM, Gottshall SL, Mark L, Pearson MS, Miller W, Shan S, et al.: Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW40 utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology 5833, 48: 658–672. 10.1016/j.neuropharm.2004.12.008
62.
Elmes SJ, Jhaveri MD, Smart D, Kendall DA, Chapman V: Cannabinoid CB2 receptor activation inhibits mechanically evoked responses of wide dynamic range dorsal horn neurons in naive rats and in rat models of inflammatory and neuropathic pain. Eur J Neurosci 2004, 20: 2311–2320. 10.1111/j.1460-9568.2004.03690.xPubMed
63.
Ibrahim MM, Porreca F, Lai J, Albrecht PJ, Rice FL, Khodorova A, Davar G, Makriyannis A, Vanderah TW, Mata HP, Malan TP Jr: CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci USA 2005, 102: 3093–3098. 10.1073/pnas.0409888102PubMedCentralPubMed
64.
Sagar DR, Kelly S, Millns PJ, O'Shaughnessey CT, Kendall DA, Chapman V: Inhibitory effects of CB1 and CB2 receptor agonists on responses of DRG neurons and dorsal horn neurons in neuropathic rats. Eur J Neurosci 2005, 22: 371–379. 10.1111/j.1460-9568.2005.04206.xPubMed
65.
Jhaveri MD, Elmes SJ, Richardson D, Barrett DA, Kendall DA, Mason R, Chapman V: Evidence for a novel functional role of cannabinoid CB receptors in the thalamus of neuropathic rats. Eur J Neurosci 2008, 27: 1722–1730. 10.1111/j.1460-9568.2008.06162.xPubMedCentralPubMed
66.
Romero-Sandoval A, Nutile-McMenemy N, DeLeo JA: Spinal microglial and perivascular cell cannabinoid receptor type 2 activation reduces behavioral hypersensitivity without tolerance after peripheral nerve injury. Anesthesiology 2008, 108: 722–734. 10.1097/ALN.0b013e318167af74PubMedCentralPubMed
67.
Yamamoto W, Mikami T, Iwamura H: Involvement of central cannabinoid CB2 receptor in reducing mechanical allodynia in a mouse model of neuropathic pain. European Journal of Pharmacology 2008, 583: 56–61. 10.1016/j.ejphar.2008.01.010PubMed
68.
Racz I, Nadal X, Alferink J, Banos JE, Rehnelt J, Martin M, Pintado B, Gutierrez-Adan A, Sanguino E, Manzanares J, et al.: Crucial role of CB(2) cannabinoid receptor in the regulation of central immune responses during neuropathic pain. J Neurosci 2008, 28: 12125–12135. 10.1523/JNEUROSCI.3400-08.2008PubMedCentralPubMed
69.
Leichsenring A, Andriske M, Backer I, Stichel CC, Lubbert H: Analgesic and antiinflammatory effects of cannabinoid receptor agonists in a rat model of neuropathic pain. Naunyn Schmiedebergs Arch Pharmacol 2009, 379: 627–636. 10.1007/s00210-008-0386-4PubMed
70.
Racz I, Nadal X, Alferink J, Banos JE, Rehnelt J, Martin M, Pintado B, Gutierrez-Adan A, Sanguino E, Bellora N, et al.: Interferon-gamma is a critical modulator of CB(2) cannabinoid receptor signaling during neuropathic pain. J Neurosci 2008, 28: 12136–12145. 10.1523/JNEUROSCI.3402-08.2008PubMedCentralPubMed
71.
Malan TP Jr, Ibrahim MM, Lai J, Vanderah TW, Makriyannis A, Porreca F: CB2 cannabinoid receptor agonists: pain relief without psychoactive effects? Curr Opin Pharmacol 2003, 3: 62–67. 10.1016/S1471-4892(02)00004-8PubMed
72.
Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R: Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992, 258: 1946–1949. 10.1126/science.1470919PubMed
73.
Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, Gopher A, Almog S, Martin BR, Compton DR, et al.: Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995, 50: 83–90. 10.1016/0006-2952(95)00109-DPubMed
74.
Hanus L, Abu-Lafi S, Fride E, Breuer A, Vogel Z, Shalev DE, Kustanovich I, Mechoulam R: 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci USA 2001, 98: 3662–3665. 10.1073/pnas.061029898PubMedCentralPubMed
75.
Porter AC, Sauer JM, Knierman MD, Becker GW, Berna MJ, Bao J, Nomikos GG, Carter P, Bymaster FP, Leese AB, Felder CC: Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 2002, 301: 1020–1024. 10.1124/jpet.301.3.1020PubMed
76.
Huang SM, Bisogno T, Trevisani M, Al-Hayani A, De Petrocellis L, Fezza F, Tognetto M, Petros TJ, Krey JF, Chu CJ, et al.: An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci USA 2002, 99: 8400–8405. 10.1073/pnas.122196999PubMedCentralPubMed
77.
LoVerme J, Russo R, La Rana G, Fu J, Farthing J, Mattace-Raso G, Meli R, Hohmann A, Calignano A, Piomelli D: Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha. J Pharmacol Exp Ther 2006, 319: 1051–1061. 10.1124/jpet.106.111385PubMed
78.
Guzman M, Lo Verme J, Fu J, Oveisi F, Blazquez C, Piomelli D: Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor alpha (PPAR-alpha). J Biol Chem 2004, 279: 27849–27854. 10.1074/jbc.M404087200PubMed
79.
Guindon J, Desroches J, Beaulieu P: The antinociceptive effects of intraplantar injections of 2-arachidonoyl glycerol are mediated by cannabinoid CB2 receptors. Br J Pharmacol 2007, 150: 693–701. 10.1038/sj.bjp.0706990PubMedCentralPubMed
80.
Ahn K, McKinney MK, Cravatt BF: Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. Chem Rev 2008, 108: 1687–1707. 10.1021/cr0782067PubMedCentralPubMed
81.
Egertova M, Simon GM, Cravatt BF, Elphick MR: Localization of N-acyl phosphatidylethanolamine phospholipase D (NAPE-PLD) expression in mouse brain: A new perspective on N-acylethanolamines as neural signaling molecules. J Comp Neurol 2008, 506: 604–615. 10.1002/cne.21568PubMed
82.
Leung D, Saghatelian A, Simon GM, Cravatt BF: Inactivation of N-acyl phosphatidylethanolamine phospholipase D reveals multiple mechanisms for the biosynthesis of endocannabinoids. Biochemistry 2006, 45: 4720–4726. 10.1021/bi060163lPubMedCentralPubMed
83.
Liu J, Wang L, Harvey-White J, Huang BX, Kim HY, Luquet S, Palmiter RD, Krystal G, Rai R, Mahadevan A, et al.: Multiple pathways involved in the biosynthesis of anandamide. Neuropharmacology 2008, 54: 1–7. 10.1016/j.neuropharm.2007.05.020PubMedCentralPubMed
84.
Bisogno T, Ligresti A, Di Marzo V: The endocannabinoid signalling system: biochemical aspects. Pharmacol Biochem Behav 2005, 81: 224–238. 10.1016/j.pbb.2005.01.027PubMed
85.
Hashimotodani Y, Ohno-Shosaku T, Maejima T, Fukami K, Kano M: Pharmacological evidence for the involvement of diacylglycerol lipase in depolarization-induced endocanabinoid release. Neuropharmacology 2008, 54: 58–67. 10.1016/j.neuropharm.2007.06.002PubMed
86.
Bisogno T, Howell F, Williams G, Minassi A, Cascio MG, Ligresti A, Matias I, Schiano-Moriello A, Paul P, Williams EJ, et al.: Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J Cell Biol 2003, 163: 463–468. 10.1083/jcb.200305129PubMedCentralPubMed
87.
Sugiura T, Kishimoto S, Oka S, Gokoh M: Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. Prog Lipid Res 2006, 45: 405–446. 10.1016/j.plipres.2006.03.003PubMed
88.
Yoshida T, Fukaya M, Uchigashima M, Miura E, Kamiya H, Kano M, Watanabe M: Localization of diacylglycerol lipase-alpha around postsynaptic spine suggests close proximity between production site of an endocannabinoid, 2-arachidonoyl-glycerol, and presynaptic cannabinoid CB1 receptor. J Neurosci 2006, 26: 4740–4751. 10.1523/JNEUROSCI.0054-06.2006PubMed
89.
Nyilas R, Gregg LC, Mackie K, Watanabe M, Zimmer A, Hohmann AG, Katona I: Molecular architecture of endocannabinoid signaling at nociceptive synapses mediating analgesia. Eur J Neurosci 2009, 29: 1964–1978. 10.1111/j.1460-9568.2009.06751.xPubMedCentralPubMed
90.
Chapman V: The cannabinoid CB1 receptor antagonist, SR141716A, selectively facilitates nociceptive responses of dorsal horn neurones in the rat. Br J Pharmacol 1999, 127: 1765–1767. 10.1038/sj.bjp.0702758PubMedCentralPubMed
91.
Maione S, De Petrocellis L, de Novellis V, Moriello AS, Petrosino S, Palazzo E, Rossi FS, Woodward DF, Di Marzo V: Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors. Br J Pharmacol 2007, 150: 766–781. 10.1038/sj.bjp.0707145PubMedCentralPubMed
92.
Beaulieu P, Bisogno T, Punwar S, Farquhar-Smith WP, Ambrosino G, Di Marzo V, Rice AS: Role of the endogenous cannabinoid system in the formalin test of persistent pain in the rat. Eur J Pharmacol 2000, 396: 85–92. 10.1016/S0014-2999(00)00226-0
93.
Walker JM, Huang SM, Strangman NM, Tsou K, Sanudo-Pena MC: Pain modulation by release of the endogenous cannabinoid anandamide. Proc Natl Acad Sci USA 1999, 96: 12198–12203. 10.1073/pnas.96.21.12198PubMedCentralPubMed
94.
Drew GM, Lau BK, Vaughan CW: Substance P drives endocannabinoid-mediated disinhibition in a midbrain descending analgesic pathway. J Neurosci 2009, 29: 7220–7229. 10.1523/JNEUROSCI.4362-08.2009PubMed
95.
Mitrirattanakul S, Ramakul N, Guerrero AV, Matsuka Y, Ono T, Iwase H, Mackie K, Faull KF, Spigelman I: Site-specific increases in peripheral cannabinoid receptors and their endogenous ligands in a model of neuropathic pain. Pain 2006, 126: 102–114. 10.1016/j.pain.2006.06.016PubMedCentralPubMed
96.
Guasti L, Richardson D, Jhaveri M, Eldeeb K, Barrett D, Elphick MR, Alexander SP, Kendall D, Michael GJ, Chapman V: Minocycline treatment inhibits microglial activation and alters spinal levels of endocannabinoids in a rat model of neuropathic pain. Mol Pain 2009, 5: 35. 10.1186/1744-8069-5-35PubMedCentralPubMed
97.
Inoue K: The function of microglia through purinergic receptors: neuropathic pain and cytokine release. Pharmacol Ther 2006, 109: 210–226. 10.1016/j.pharmthera.2005.07.001PubMed
98.
Carrier EJ, Kearn CS, Barkmeier AJ, Breese NM, Yang W, Nithipatikom K, Pfister SL, Campbell WB, Hillard CJ: Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism. Mol Pharmacol 2004, 65: 999–1007. 10.1124/mol.65.4.999PubMed
99.
Muccioli GG, Stella N: Microglia produce and hydrolyze palmitoylethanolamide. Neuropharmacology 2008, 54: 16–22. 10.1016/j.neuropharm.2007.05.015PubMedCentralPubMed
100.
Muccioli GG, Xu C, Odah E, Cudaback E, Cisneros JA, Lambert DM, Lopez Rodriguez ML, Bajjalieh S, Stella N: Identification of a novel endocannabinoid-hydrolyzing enzyme expressed by microglial cells. J Neurosci 2007, 27: 2883–2889. 10.1523/JNEUROSCI.4830-06.2007PubMed
101.
Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB: Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 1996, 384: 83–87. 10.1038/384083a0PubMed
102.
Vandevoorde S, Lambert DM: The multiple pathways of endocannabinoid metabolism: a zoom out. Chem Biodivers 2007, 4: 1858–1881. 10.1002/cbdv.200790156PubMed
103.
Deutsch DG, Chin SA: Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem Pharmacol 1993, 46: 791–796. 10.1016/0006-2952(93)90486-GPubMed
104.
Wei BQ, Mikkelsen TS, McKinney MK, Lander ES, Cravatt BF: A second fatty acid amide hydrolase with variable distribution among placental mammals. J Biol Chem 2006, 281: 36569–36578. 10.1074/jbc.M606646200PubMed
105.
Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL, Kathuria S, Piomelli D: Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci USA 2002, 99: 10819–10824. 10.1073/pnas.152334899PubMedCentralPubMed
106.
Vandevoorde S, Jonsson KO, Labar G, Persson E, Lambert DM, Fowler CJ: Lack of selectivity of URB602 for 2-oleoylglycerol compared to anandamide hydrolysis in vitro. Br J Pharmacol 2007, 150: 186–191. 10.1038/sj.bjp.0706971PubMedCentralPubMed
107.
Tsuboi K, Takezaki N, Ueda N: The N-acylethanolamine-hydrolyzing acid amidase (NAAA). Chem Biodivers 2007, 4: 1914–1925. 10.1002/cbdv.200790159PubMed
108.
Fowler CJ: The contribution of cyclooxygenase-2 to endocannabinoid metabolism and action. Br J Pharmacol 2007, 152: 594–601. 10.1038/sj.bjp.0707379PubMedCentralPubMed
109.
Samad TA, Moore KA, Sapirstein A, Billet S, Allchorne A, Poole S, Bonventre JV, Woolf CJ: Interleukin-1beta-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature 2001, 410: 471–475. 10.1038/35068566PubMed
110.
Kozak KR, Crews BC, Ray JL, Tai HH, Morrow JD, Marnett LJ: Metabolism of prostaglandin glycerol esters and prostaglandin ethanolamides in vitro and in vivo. J Biol Chem 2001, 276: 36993–36998. 10.1074/jbc.M105854200PubMed
111.
Kozak KR, Marnett LJ: Oxidative metabolism of endocannabinoids. Prostaglandins Leukot Essent Fatty Acids 2002, 66: 211–220. 10.1054/plef.2001.0359PubMed
112.
Burstein SH, Rossetti RG, Yagen B, Zurier RB: Oxidative metabolism of anandamide. Prostaglandins Other Lipid Mediat 2000, 61: 29–41. 10.1016/S0090-6980(00)00053-8PubMed
113.
Matias I, Chen J, De Petrocellis L, Bisogno T, Ligresti A, Fezza F, Krauss AH, Shi L, Protzman CE, Li C, et al.: Prostaglandin ethanolamides (prostamides): in vitro pharmacology and metabolism. J Pharmacol Exp Ther 2004, 309: 745–757. 10.1124/jpet.103.061705PubMed
114.
Weber A, Ni J, Ling KH, Acheampong A, Tang-Liu DD, Burk R, Cravatt BF, Woodward D: Formation of prostamides from anandamide in FAAH knockout mice analyzed by HPLC with tandem mass spectrometry. J Lipid Res 2004, 45: 757–763. 10.1194/jlr.M300475-JLR200PubMed
115.
Sang N, Zhang J, Chen C: PGE2 glycerol ester, a COX-2 oxidative metabolite of 2-arachidonoyl glycerol, modulates inhibitory synaptic transmission in mouse hippocampal neurons. J Physiol 2006, 572: 735–745.PubMedCentralPubMed
116.
Sang N, Zhang J, Chen C: COX-2 oxidative metabolite of endocannabinoid 2-AG enhances excitatory glutamatergic synaptic transmission and induces neurotoxicity. J Neurochem 2007, 102: 1966–1977. 10.1111/j.1471-4159.2007.04668.xPubMed
117.
Hu SS, Bradshaw HB, Chen JS, Tan B, Walker JM: Prostaglandin E2 glycerol ester, an endogenous COX-2 metabolite of 2-arachidonoylglycerol, induces hyperalgesia and modulates NFkappaB activity. Br J Pharmacol 2008, 153: 1538–1549. 10.1038/bjp.2008.33PubMedCentralPubMed
118.
Snider NT, Nast JA, Tesmer LA, Hollenberg PF: A cytochrome P450-derived epoxygenated metabolite of anandamide is a potent cannabinoid receptor 2-selective agonist. Mol Pharmacol 2009, 75: 965–972. 10.1124/mol.108.053439PubMedCentralPubMed
119.
Chen JK, Chen J, Imig JD, Wei S, Hachey DL, Guthi JS, Falck JR, Capdevila JH, Harris RC: Identification of novel endogenous cytochrome p450 arachidonate metabolites with high affinity for cannabinoid receptors. J Biol Chem 2008, 283: 24514–24524. 10.1074/jbc.M709873200PubMedCentralPubMed
120.
Cowart LA, Wei S, Hsu MH, Johnson EF, Krishna MU, Falck JR, Capdevila JH: The CYP4A isoforms hydroxylate epoxyeicosatrienoic acids to form high affinity peroxisome proliferator-activated receptor ligands. J Biol Chem 2002, 277: 35105–35112. 10.1074/jbc.M201575200PubMed
121.
Fang X, Hu S, Xu B, Snyder GD, Harmon S, Yao J, Liu Y, Sangras B, Falck JR, Weintraub NL, Spector AA: 14,15-Dihydroxyeicosatrienoic acid activates peroxisome proliferator-activated receptor-alpha. Am J Physiol Heart Circ Physiol 2006, 290: H55–63. 10.1152/ajpheart.00427.2005PubMed
122.
Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR, Lichtman AH: Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA 2001, 98: 9371–9376. 10.1073/pnas.161191698PubMedCentralPubMed
123.
Lichtman AH, Shelton CC, Advani T, Cravatt BF: Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia. Pain 2004, 109: 319–327. 10.1016/j.pain.2004.01.022PubMed
124.
Jayamanne A, Greenwood R, Mitchell VA, Aslan S, Piomelli D, Vaughan CW: Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br J Pharmacol 2006, 147: 281–288. 10.1038/sj.bjp.0706510PubMedCentralPubMed
125.
Chang L, Luo L, Palmer JA, Sutton S, Wilson SJ, Barbier AJ, Breitenbucher JG, Chaplan SR, Webb M: Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms. Br J Pharmacol 2006, 148: 102–113. 10.1038/sj.bjp.0706699PubMedCentralPubMed
126.
Lichtman A, Leung D, Shelton C, Saghatelian A, Hardouin C, Boger D, Cravatt B: Reversible Inhibitors of Fatty Acid Amide Hydrolase That Promote Analgesia: Evidence for an Unprecedented Combination of Potency and Selectivity. Journal of Pharmacology and Experimental Therapeutics 2004, 311: 441–448. 10.1124/jpet.104.069401PubMed
127.
Kathuria S, Gaetani S, Fegley D, Valino F, Duranti A, Tontini A, Mor M, Tarzia G, La Rana G, Calignano A, et al.: Modulation of anxiety through blockade of anandamide hydrolysis. Nature Medicine 2003, 9: 76–81. 10.1038/nm803PubMed
128.
Fegley D, Gaetani S, Duranti A, Tontini A, Mor M, Tarzia G, Piomelli D: Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther 2005, 313: 352–358. 10.1124/jpet.104.078980PubMed
129.
Russo R, Loverme J, La Rana G, Compton T, Parrot J, Duranti A, Tontini A, Mor M, Tarzia G, Calignano A, Piomelli D: The fatty-acid amide hydrolase inhibitor URB597 (cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice. J Pharmacol Exp Ther 2007, 322: 236–242. 10.1124/jpet.107.119941PubMed
130.
Zhang D, Saraf A, Kolasa T, Bhatia P, Zheng GZ, Patel M, Lannoye GS, Richardson P, Stewart A, Rogers JC, et al.: Fatty acid amide hydrolase inhibitors display broad selectivity and inhibit multiple carboxylesterases as off-targets. Neuropharmacology 2007, 52: 1095–1105. 10.1016/j.neuropharm.2006.11.009PubMed
131.
Karbarz MJ, Luo L, Chang L, Tham CS, Palmer JA, Wilson SJ, Wennerholm ML, Brown SM, Scott BP, Apodaca RL, et al.: Biochemical and Biological Properties of 4-(3-phenyl-[1,2,4]thiadiazol-5-yl)-piperazine-1-carboxylic acid phenylamide, a Mechanism-Based Inhibitor of Fatty Acid Amide Hydrolase. Anesthesia and Analgesia 2009, 108: 316–329. 10.1213/ane.0b013e31818c7cbdPubMed
132.
Ahn K, Johnson DS, Mileni M, Beidler D, Long JZ, McKinney MK, Weerapana E, Sadagopan N, Liimatta M, Smith SE, et al.: Discovery and Characterization of a Highly Selective FAAH Inhibitor that Reduces Inflammatory Pain. Chemistry & Biology 2009, 16: 411–420. 10.1016/j.chembiol.2009.02.013
133.
Kinsey SG, Long JZ, O'Neal ST, Abdullah RA, Poklis JL, Boger DL, Cravatt BF, Lichtman AH: Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain. J Pharmacol Exp Ther 2009, 330: 902–910. 10.1124/jpet.109.155465PubMedCentralPubMed
134.
Jhaveri MD, Richardson D, Kendall DA, Barrett DA, Chapman V: Analgesic effects of fatty acid amide hydrolase inhibition in a rat model of neuropathic pain. J Neurosci 2006, 26: 13318–13327. 10.1523/JNEUROSCI.3326-06.2006PubMed
135.
Comelli F, Giagnoni G, Bettoni I, Colleoni M, Costa B: The inhibition of monoacylglycerol lipase by URB602 showed an anti-inflammatory and anti-nociceptive effect in a murine model of acute inflammation. Br J Pharmacol 2007, 152: 787–794. 10.1038/sj.bjp.0707425PubMedCentralPubMed
136.
Long JZ, Li WW, Booker L, Burston JJ, Kinsey SG, Schlosburg JE, Pavon FJ, Serrano AM, Selley DE, Parsons LH, et al.: Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nature Chemical Biology 2009, 5: 37–44. 10.1038/nchembio.129PubMedCentralPubMed
137.
Bisogno T, Ortar G, Petrosino S, Morera E, Palazzo E, Nalli M, Maione S, Di Marzo V: Development of a potent inhibitor of 2-arachidonoylglycerol hydrolysis with antinociceptive activity in vivo. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 2009, 1791: 53–60. 10.1016/j.bbalip.2008.10.007
138.
D'Agostino G, La Rana G, Russo R, Sasso O, Iacono A, Esposito E, Mattace Raso G, Cuzzocrea S, Loverme J, Piomelli D, et al.: Central administration of palmitoylethanolamide reduces hyperalgesia in mice via inhibition of NF-kappaB nuclear signalling in dorsal root ganglia. Eur J Pharmacol 2009, 613: 54–59. 10.1016/j.ejphar.2009.04.022PubMed
139.
Petrosino S, Palazzo E, de Novellis V, Bisogno T, Rossi F, Maione S, Di Marzo V: Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats. Neuropharmacology 2007, 52: 415–422. 10.1016/j.neuropharm.2006.08.011PubMed
140.
Minami T, Nakano H, Kobayashi T, Sugimoto Y, Ushikubi F, Ichikawa A, Narumiya S, Ito S: Characterization of EP receptor subtypes responsible for prostaglandin E2-induced pain responses by use of EP1 and EP3 receptor knockout mice. Br J Pharmacol 2001, 133: 438–444. 10.1038/sj.bjp.0704092PubMedCentralPubMed
141.
Minami T, Uda R, Horiguchi S, Ito S, Hyodo M, Hayaishi O: Allodynia evoked by intrathecal administration of prostaglandin F2 alpha to conscious mice. Pain 1992, 50: 223–229. 10.1016/0304-3959(92)90166-9PubMed
142.
Piomelli D: The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 2003, 4: 873–884. 10.1038/nrn1247PubMed
143.
Schmid HH: Pathways and mechanisms of N-acylethanolamine biosynthesis: can anandamide be generated selectively? Chem Phys Lipids 2000, 108: 71–87. 10.1016/S0009-3084(00)00188-2PubMed
144.
Simon GM, Cravatt BF: Anandamide biosynthesis catalyzed by the phosphodiesterase GDE1 and detection of glycerophospho-N-acyl ethanolamine precursors in mouse brain. J Biol Chem 2008, 283: 9341–9349. 10.1074/jbc.M707807200PubMedCentralPubMed
Metadata
Title
Dynamic regulation of the endocannabinoid system: implications for analgesia
Authors
Devi Rani Sagar
A Gemma Gaw
Bright N Okine
Stephen G Woodhams
Amy Wong
David A Kendall
Victoria Chapman
Publication date
01-12-2009
Publisher
BioMed Central
Published in
Molecular Pain / Issue 1/2009
Electronic ISSN: 1744-8069
DOI
https://doi.org/10.1186/1744-8069-5-59

Other articles of this Issue 1/2009

Molecular Pain 1/2009 Go to the issue

Research

Genetic variation in the serotonin transporter gene (5-HTTLPR, rs25531) influences the analgesic response to the short acting opioid Remifentanil in humans

Research

Excitatory neurotransmitters in brain regions in interictal migraine patients

Research

High concentrations of morphine sensitize and activate mouse dorsal root ganglia via TRPV1 and TRPA1 receptors

Research

Expression and function of proton-sensing G-protein-coupled receptors in inflammatory pain

Research

Oxaliplatin-induced loss of phosphorylated heavy neurofilament subunit neuronal immunoreactivity in rat DRG tissue

Short report

Intrathecal delivery of PDGF produces tactile allodynia through its receptors in spinal microglia